Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
Generated Narrative: Evidence 293987
version: 3; Last updated: 2024-12-14 08:46:28+0000
Profile: InterventionOnlyEvidence
url: https://fevir.net/resources/Evidence/293987
identifier: FEvIR Object Identifier/https://fevir.net/FOI/293987, outcomeId/313963, picoId/85798, sectionId/73215
name: Serious_hyperglycaemia_Intervention_Evidence_from_MAGICapp_313963
title: MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in SGLT2 inhibitors Group in Adults with type 2 diabetes
status: Active
publisher: Computable Publishing LLC
contact: support@computablepublishing.com
author: Computable Publishing®: MAGIC-to-FEvIR Converter:
Code | Value[x] |
Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication: Evidence Communication | InterventionOnlyEvidence |
copyright:
https://creativecommons.org/licenses/by-nc-sa/4.0/
Type | ResourceReference |
Part Of | MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report) |
description:
This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.
variableDefinition
description:
Adults with type 2 diabetes -- SGLT2 inhibitors
variableRole: Population
observed: SGLT2 inhibitors Group in Adults with type 2 diabetes
variableDefinition
description:
Serious hyperglycaemia
variableRole: Outcome
observed: Serious hyperglycaemia
Description | StatisticType | Quantity |
Risk 1.5% | Proportion | 0.015 |